Commentary
Commentary
Time to end direct-to-consumer ads, says physician
While these ads urge patients to try expensive “newest and latest” treatments, pharmacy benefits plans are working with health care insurance...
Commentary
10 ways docs sabotage their patients’ weight loss journeys
Stopping medications for obesity when weight is lost. Do you also stop blood pressure medications when they normalize a patient’s blood pressure...
Commentary
Lessons from the longest study on happiness
To some surprise, researchers determined that good relationships were the most significant predictor of health and happiness during aging.
Commentary
Brisk walking: No-cost option for patients to improve cancer outcomes
The bottom line is that physical activity is positive, is not expensive, and focuses on what the individual patient can do for themselves.
Commentary
Conflicting blood pressure targets: Déjà vu all over again
Arguing about 140/90 mm Hg or 130/80 mm Hg is less important than acknowledging that we should be aggressive in screening for and treating...
Commentary
A teenage girl refuses more cancer treatment; her father disagrees
For those who have recurrent disease and now face only experimental options – if they say no, that’s something we really have to listen to very...
Commentary
The surprising occupations with higher-than-expected ovarian cancer rates
This is how these types of studies work; they tend to raise more questions than they answer.
Opinion
Death anxiety in psychiatry and society: Facing our fears and embracing life
The fear of death can be therapeutic and motivating, but it can also be pathological and lead to a lack of motivation or drive.
News
Dangerous grandparents
It can be a touchy subject in families, but grandparents should be reminded that their behavior may be setting a bad example or putting their...
Commentary
Discontinuing Disease-Modifying Therapies in Nonactive Secondary Progressive MS:Review of the Evidence
Background: There are currently no disease-modifying therapies (DMTs) on the market approved for nonactive secondary...